Open positions

Investors

The Future of Diagnostics: Precision, Prediction, and Non-Invasive Insight

The global diagnostics market is undergoing a seismic shift. Valued at over $100 billion in 2024, the in-vitro diagnostics sector is expanding rapidly, driven by an urgent need for tools that can detect chronic diseases earlier and more cost-efficiently. With healthcare costs rising globally, the focus is moving from reactive treatment to proactive, data-driven prevention.

  • Time-resolved fluorescence based assay for rapid detection of Escherichia coli (Analytical Biochemistry, 2015) / Kulpakko J., Kopra K. and Hänninen P.

  • Rapid time-resolved luminescence based screening of bacteria in urine with luminescence modulating biosensing phages (Analytical Biochemistry, 2019) / Kulpakko, J., Rantakokko-Jalava, K., Eerola, E., & Hänninen P.

  • Detecting disease associated biomarkers by luminescence modulating phages (Scientific Reports, 2022) / Kulpakko J., Juusti V., Rannikko A., and Hänninen P.

  • Biophysical properties of bifunctional phage-biosensor (Viruses, 2023) / Juusti V., Kulpakko J. Cudjoe E., Pimenoff V, and Hänninen P.

  • Phage-biosensor for classification of metastatic urological cancers from urine (Life, 2024) / Juusti V., Rannikko A., Laurila A., Sundvall M., Hänninen P. and Kulpakko J.

Disease-Specific Patents

  • A method for detecting a prostate cancer biomarker (EP3916391, US11796470, CA3116958, CN202110532894.9)
  • A method for determining likelihood of and an inflammatory gastrointestinal tract disease (EP20169854.5, US11891649, CA3114536), extended to China

Horizontal Patents

  • Phage-Based Method for Detecting Biomarkers (3226135, 202280047805.4, 22737938.5, 18/576381)
  • A method for determining Escherichia coli (3874270)
  • Mucosa analysis (126519 / 3362796)
  • Method for fingerprinting samples such as wine or water (EP2430447B1)
Shareholders

Why the Market is Prime for Innovation

  • The Rise of Non-Invasive Testing: Non-invasive samples like urine hold an enormous amount of untapped health information. The global Urinalysis market is expected to reach $6.8 billion by 2030, fueled by a demand for frequent, painless monitoring that improves patient compliance and clinical outcomes.
  • The Power of Multi-Omics and AI: Integrating molecular profiles—including genomics and proteomics—with AI-driven analysis allows for the prediction of disease risk years before symptoms appear. This “multi-omics” approach is the new standard for precision medicine.
  • Economic Impact: Early detection is not just a clinical win; it is an economic necessity. Every dollar invested in laboratory diagnostics can save up to three dollars in overall healthcare costs by preventing unnecessary treatments and hospitalizations.

AQ Biotech: At the Intersection of Bioscience and Scalability

AQ Biotech is positioned to lead this transformation. Our technology bridges the gap between laboratory deeptech and commercial scalability:

  • Phage-biosensor method: Our proprietary biosensor platform offers a versatile foundation for detecting a wide range of diseases and respective biomarkers
  • Validated IPR portfolio: EU, North America and China patents covering both horizontal methods and disease-specific biomarkers
  • Peer-reviewed excellence: Our methods are backed by continuous scientific publications with tier 1 clinicians in high-impact journals